JP2023067881A5 - - Google Patents

Download PDF

Info

Publication number
JP2023067881A5
JP2023067881A5 JP2023021625A JP2023021625A JP2023067881A5 JP 2023067881 A5 JP2023067881 A5 JP 2023067881A5 JP 2023021625 A JP2023021625 A JP 2023021625A JP 2023021625 A JP2023021625 A JP 2023021625A JP 2023067881 A5 JP2023067881 A5 JP 2023067881A5
Authority
JP
Japan
Prior art keywords
group
compound according
salt
formula
edema
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023021625A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023067881A (ja
JP7703587B2 (ja
Filing date
Publication date
Priority claimed from PCT/EP2021/053286 external-priority patent/WO2021160718A1/en
Application filed filed Critical
Publication of JP2023067881A publication Critical patent/JP2023067881A/ja
Publication of JP2023067881A5 publication Critical patent/JP2023067881A5/ja
Priority to JP2025107413A priority Critical patent/JP2025148369A/ja
Application granted granted Critical
Publication of JP7703587B2 publication Critical patent/JP7703587B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023021625A 2020-02-13 2023-02-15 血漿カリクレイン阻害剤としての複素芳香族カルボキシアミド誘導体 Active JP7703587B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025107413A JP2025148369A (ja) 2020-02-13 2025-06-25 血漿カリクレイン阻害剤としての複素芳香族カルボキシアミド誘導体

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP20157259.1 2020-02-13
EP20157259 2020-02-13
PCT/EP2021/053286 WO2021160718A1 (en) 2020-02-13 2021-02-11 Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors
JP2022514811A JP7230277B2 (ja) 2020-02-13 2021-02-11 血漿カリクレイン阻害剤としての複素芳香族カルボキシアミド誘導体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022514811A Division JP7230277B2 (ja) 2020-02-13 2021-02-11 血漿カリクレイン阻害剤としての複素芳香族カルボキシアミド誘導体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025107413A Division JP2025148369A (ja) 2020-02-13 2025-06-25 血漿カリクレイン阻害剤としての複素芳香族カルボキシアミド誘導体

Publications (3)

Publication Number Publication Date
JP2023067881A JP2023067881A (ja) 2023-05-16
JP2023067881A5 true JP2023067881A5 (https=) 2024-02-20
JP7703587B2 JP7703587B2 (ja) 2025-07-07

Family

ID=69591572

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022514811A Active JP7230277B2 (ja) 2020-02-13 2021-02-11 血漿カリクレイン阻害剤としての複素芳香族カルボキシアミド誘導体
JP2023021625A Active JP7703587B2 (ja) 2020-02-13 2023-02-15 血漿カリクレイン阻害剤としての複素芳香族カルボキシアミド誘導体
JP2025107413A Pending JP2025148369A (ja) 2020-02-13 2025-06-25 血漿カリクレイン阻害剤としての複素芳香族カルボキシアミド誘導体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022514811A Active JP7230277B2 (ja) 2020-02-13 2021-02-11 血漿カリクレイン阻害剤としての複素芳香族カルボキシアミド誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025107413A Pending JP2025148369A (ja) 2020-02-13 2025-06-25 血漿カリクレイン阻害剤としての複素芳香族カルボキシアミド誘導体

Country Status (22)

Country Link
US (3) US11760745B2 (https=)
EP (1) EP4103562A1 (https=)
JP (3) JP7230277B2 (https=)
KR (1) KR20220141333A (https=)
CN (2) CN116120287B (https=)
AR (2) AR121341A1 (https=)
AU (1) AU2021218952A1 (https=)
BR (1) BR112022013979A2 (https=)
CA (1) CA3168690A1 (https=)
CL (2) CL2022002101A1 (https=)
CO (1) CO2022011254A2 (https=)
CR (2) CR20220382A (https=)
DO (2) DOP2022000157A (https=)
EC (1) ECSP22062410A (https=)
IL (2) IL320007A (https=)
JO (1) JOP20220186A1 (https=)
MX (3) MX2022009941A (https=)
PE (2) PE20231985A1 (https=)
SA (1) SA522440127B1 (https=)
TW (2) TWI873290B (https=)
UA (1) UA130722C2 (https=)
WO (1) WO2021160718A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112839711A (zh) 2018-10-10 2021-05-25 勃林格殷格翰国际有限公司 作为血浆激肽释放酶抑制剂的苯基四唑衍生物
TWI873290B (zh) 2020-02-13 2025-02-21 德商百靈佳殷格翰國際股份有限公司 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物
TW202144331A (zh) 2020-02-13 2021-12-01 德商百靈佳殷格翰國際股份有限公司 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物
WO2025001956A1 (zh) * 2023-06-30 2025-01-02 远森制药(杭州)有限公司 杂芳族甲酰胺类化合物及其在医药上的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
DE10207037A1 (de) * 2002-02-20 2003-08-28 Bayer Cropscience Gmbh 2-Amino-4-bicyclyamino-6H-1,3.5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
DE10230012A1 (de) * 2002-07-04 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 5,6-Dihydro-4H-imidazo[4,5,1-ij]chinoline,ihre Herstellung und ihre Verwendung als Arzneimittel
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
JP2005089362A (ja) 2003-09-17 2005-04-07 Sumitomo Chemical Co Ltd アリールピラゾリン化合物及びその用途
EP2259679A4 (en) 2008-01-31 2011-09-14 Joslin Diabetes Ct METHODS OF TREATING KALLIKREIN RELATED DISORDERS
NZ602266A (en) * 2010-02-11 2014-05-30 Bristol Myers Squibb Co Macrocycles as factor xia inhibitors
EP2807156A1 (en) 2012-01-27 2014-12-03 Novartis AG Aminopyridine derivatives as plasma kallikrein inhibitors
US20140378474A1 (en) 2012-01-27 2014-12-25 Novartis Ag 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
EP2999697B1 (en) 2013-05-23 2017-04-19 Kalvista Pharmaceuticals Limited Heterocyclic derivates
US10981893B2 (en) 2015-07-01 2021-04-20 Attune Pharmaceuticals, Inc. Therapeutic inhibitory compounds
EP3368524B1 (en) 2015-10-27 2021-08-18 Boehringer Ingelheim International GmbH Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
WO2017072020A1 (en) 2015-10-27 2017-05-04 Boehringer Ingelheim International Gmbh Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
DK3464271T3 (da) 2016-05-31 2020-06-15 Kalvista Pharmaceuticals Ltd Pyrazolderivater som plasma-kallikreininhibitorer
CN110022875A (zh) 2016-07-11 2019-07-16 莱福斯希医药公司 治疗性抑制化合物
US10501440B2 (en) 2017-04-21 2019-12-10 Boehringer Ingelheim International Gmbh Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
CA3063934A1 (en) * 2017-05-17 2018-11-22 Denali Therapeutics Inc. Kinase inhibitors and uses thereof
JP6828191B2 (ja) 2018-08-16 2021-02-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 血漿カリクレイン阻害剤としての複素芳香族カルボキサミド誘導体
DK4031547T3 (da) 2019-09-18 2024-09-09 Takeda Pharmaceuticals Co Plasmakallikreininhibitorer og anvendelser deraf
TWI873290B (zh) 2020-02-13 2025-02-21 德商百靈佳殷格翰國際股份有限公司 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物
TW202144331A (zh) 2020-02-13 2021-12-01 德商百靈佳殷格翰國際股份有限公司 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物

Similar Documents

Publication Publication Date Title
JP2023067881A5 (https=)
AU2022270115B2 (en) Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors
JP7566889B2 (ja) Il-17aモジュレーターおよびその使用
CN115244056A (zh) 稠合咪唑类衍生物、其制备方法及其在医药上的应用
JP6269862B2 (ja) 三環性スピロ化合物
JP2011509309A5 (https=)
JP2022081661A5 (https=)
JPH01283220A (ja) 血圧降下増強剤
CN115175905A (zh) Zeste增强子同源物2抑制剂及其用途
JP2021527660A (ja) RORγtのモジュレータとしてのフェニル及びピリジニル置換イミダゾール
JPH07502487A (ja) 血糖低下性チアゾリジンジオンとその中間体
JP2020517619A5 (https=)
JP7338711B2 (ja) Dpアンタゴニスト
CA2881260C (en) Crystalline forms of dihydropyrimidine derivatives
KR100292928B1 (ko) 치환된헥사하이드로벤조페난트리딘
JP2024099528A5 (https=)
TW200526205A (en) Nitrogen-containing heterocyclic compound, and medicine containing such compound as effective ingredient
CN114075123B (zh) 苄胺类衍生物及其制备方法与用途
JP2002527506A (ja) アセチルコリン受容体拮抗薬としてのエピバチジンアナログ
JP2023544446A5 (https=)
CA3182610C (en) 2-oxo-oxazolidine-5-carboxamides as nav1.8 inhibitors
RU2007134267A (ru) Фармацевтическая композиция, обладающая противодиабетической, гиполипидемической, гипогликемической и гипохолестеринемической активностью, способ ее получения и способы лечения указанных заболеваний
CA3182610A1 (en) 2-oxo-oxazolidine-5-carboxamides as nav1.8 inhibitors
JP2001508399A (ja) 5―htレセプターアンタゴニストとしてのインドール誘導体
JPS6222757A (ja) 置換アニリノ−2−ピロリン誘導体